Edinburgh International Conference Centre

ICAS Redefines Accountancy Training in UK First

Retrieved on: 
Monday, March 25, 2024
Sustainability, Environment, Finance, Accounting, Professional Services, Education, Training, Business, Conference, Learning, Chartered accountant, Trust, Ethics, History, CAS, Microsoft Power BI, Student, Edinburgh International Conference Centre, Xero, ICAS, Tutoring

The Institute of Chartered Accountants of Scotland ( ICAS ) has today announced the biggest shake up in how it trains accountancy students in its 170-year history.

Key Points: 
  • The Institute of Chartered Accountants of Scotland ( ICAS ) has today announced the biggest shake up in how it trains accountancy students in its 170-year history.
  • The new syllabus will make sure that the Chartered Accountant (CA) qualification remains relevant in an evolving global business landscape and from 22 March, ICAS students will learn through a UK first training model.
  • Bruce Cartwright CA, CEO at ICAS said: “Throughout our 170-year history, ICAS has constantly reinvented itself to remain relevant in an ever-changing world.
  • Training with ICAS will also mean that students can study online, but also access in person workshops and tutor time.

M6P Therapeutics Presents Novel AAV Gene Therapy Approach for the Treatment of Gaucher Disease at the ESGCT 29th Annual Congress

Retrieved on: 
Tuesday, October 11, 2022
Health, Other Science, General Health, Research, Science, Biotechnology, Congress, ESGCT, LSD, Therapy, Conference, Animal, Cell, Drug development, Gene, Publication, Glycogen storage disease, Tissue, Program, European Society of Gene and Cell Therapy, Technology, R, Gaucher's disease, Edinburgh International Conference Centre, Neuron, AAV, Phosphorylation, Metabolic disorder, Glycosphingolipid, CEO, A-DNA, CNS, Brain, Â, Mannose, GBA1, Central nervous system, M6P, Poster, Pharmaceutical industry, Fine chemical, Gaucher

The Congress takes place in-person and virtually in Edinburgh, Scotland from Oct. 11-14, 2022 at the Edinburgh International Conference Centre.

Key Points: 
  • The Congress takes place in-person and virtually in Edinburgh, Scotland from Oct. 11-14, 2022 at the Edinburgh International Conference Centre.
  • The data from this preclinical study illustrate the potential of our AAV-GBA-S1S3 gene therapy candidate for the treatment of Gaucher disease, including neuronopathic phenotypes, said Pawel Krysiak, President and CEO of M6P Therapeutics.
  • M012 is part of our pipeline of candidates leveraging a first-in-class co-expression S1S3 platform technology for the treatment of lysosomal storage disorders.
  • Gene therapy could be a potential therapeutic approach to treat all three types of Gaucher disease.

Precision BioSciences to Present at the European Society of Gene & Cell Therapy (ESGCT) 29th Congress

Retrieved on: 
Tuesday, October 11, 2022
Research, Infectious Diseases, Genetics, Clinical Trials, Stem Cells, Biotechnology, General Health, Pharmaceutical, Health, Science, Congress, ESGCT, Conference, Cell, Gene, Gene editing, Nasdaq, European Society of Gene and Cell Therapy, CAR, List, Infection, Edinburgh International Conference Centre, 2021 Essex County Council election, Genome, Poster, Vaccine

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.

Key Points: 
  • Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that three abstracts have been accepted by the European Society of Gene & Cell Therapy (ESGCT) for one oral and two poster presentations at the upcoming Congress on October 11-14, 2022, at the Edinburgh International Conference Centre.
  • Precision BioSciences, Inc. is a clinical stage biotechnology company dedicated to improving life (DTIL) with its novel and proprietary ARCUS genome editing platform.
  • ARCUS is a highly precise and versatile genome editing platform that was designed with therapeutic safety, delivery, and control in mind.
  • For more information about Precision BioSciences, please visit www.precisionbiosciences.com .

Renovacor Announces Upcoming Presentation at the 29th European Society of Gene & Cell Therapy Congress

Retrieved on: 
Monday, October 10, 2022
Biotechnology, Health, Genetics, Clinical Trials, Cardiology, Quality of life, Congress, ESGCT, Disease, Conference, IND, NYSE, Cell, Patient, Gene, CMC, Analytic, RCOR, European Society of Gene and Cell Therapy, Private Securities Litigation Reform Act, Edinburgh International Conference Centre, Company, U.S. Securities and Exchange Commission, AAV, Heart failure, Securities & Exchange Commission of Pakistan, DCM, Intellectual property, Forward-looking statement, FDA, COVID-19, Pharmaceutical industry

The congress is taking place from October 11 14, 2022, at the Edinburgh International Conference Centre in Edinburgh, Scotland.

Key Points: 
  • The congress is taking place from October 11 14, 2022, at the Edinburgh International Conference Centre in Edinburgh, Scotland.
  • REN-001 is an AAV-based gene therapy targeting BAG3-associated dilated cardiomyopathy (DCM), a severe form of heart failure.
  • The upcoming poster (P046), titled, Analytical and biophysical characterization of a rAAV9 vector for in-vivo gene therapy to treat dilated cardiomyopathy, will be presented from 5:30 7:15 p.m. British Summer Time on October 14, 2022.
  • Renovacor is a biotechnology company focused on delivering innovative precision therapies to improve the lives of patients and families battling genetically-driven cardiovascular and mechanistically-related diseases.

Cabaletta Bio to Present at the 29th Annual Congress of the European Society of Gene & Cell Therapy

Retrieved on: 
Thursday, October 6, 2022
LinkedIn, Congress, ESGCT, Disease, Conference, Infection, Poster, Immunity, Degenerative disease, Cell, Patient, Gene, Glomerulonephritis, CAR, European Society of Gene and Cell Therapy, Haemophilia, MuSK protein, Pemphigus, Edinburgh International Conference Centre, Health, GLOBE, MPV, Pharmaceutical industry, Vaccine

Presentation materials will be made available under the Posters & Publications section of the Companys website shortly after the event.

Key Points: 
  • Presentation materials will be made available under the Posters & Publications section of the Companys website shortly after the event.
  • While CAR T cells typically contain a CD 19-targeting molecule, CAAR T cells express an autoantibody-targeted antigen on their surface.
  • The co-stimulatory domain and the signaling domain of both a CAR T cell and a CAAR T cell carry out the same activation and cytotoxic functions.
  • Cabaletta Bios headquarters are located in Philadelphia, PA. For more information, visit www.cabalettabio.com and follow us on LinkedIn.

Hyatt Announces Milestone Development Plans for Hyatt Centric Edinburgh Haymarket

Retrieved on: 
Wednesday, June 1, 2022
Lodging, Destinations, Travel, Vacation, Public expenditure, Company, Conference, Tsunami, Unemployment, COVID-19 vaccine, Failure, COVID-19 testing, Edinburgh College, NYSE, COVID-19, List of national museums, Foster and Partners, Hyatt, History, Alderbrook Resort & Spa, Share repurchase, Pacific typhoon season, Trade, Industry, Heart, Walking, Old Town, JDV, Partner, Travel, Tornado, Edinburgh Castle, Vaccine, EICC, Infection, Acquisition, Edinburgh International Conference Centre, SEC, Culture, Brookwater Golf and Spa Resort, Wildfire, Private Securities Litigation Reform Act, Internet, Danbo, Facebook, Food, Form 10-K, George Street, Annual report, Flood, ICA, Policy, ALG, Environment, National Museum of Scotland, Earthquake, RevPAR, Student, Growth, Edinburgh Airport, Pandemic, Park, Instagram, Person, Hotel

Hyatt Hotels Corporation (NYSE: H) announced today that a Hyatt affiliate has entered into a franchise agreement with Edinburgh International Conference Centre (EICC) for Hyatt Centric Edinburgh Haymarket.

Key Points: 
  • Hyatt Hotels Corporation (NYSE: H) announced today that a Hyatt affiliate has entered into a franchise agreement with Edinburgh International Conference Centre (EICC) for Hyatt Centric Edinburgh Haymarket.
  • Located less than 1,000 feet (300 meters) from the EICC, Hyatt Centric Edinburgh Haymarket will be a part of the Haymarket Edinburgh development, which will encompass office blocks and retail units.
  • Hyatt Centric Edinburgh Haymarket will join 16 Hyatt-branded properties across the U.K., and will mark the second Hyatt Centric hotel in the country, joining Hyatt Centric Cambridge .
  • The Company's offering includes the Park Hyatt, Miraval, Grand Hyatt, Alila, Andaz, The Unbound Collection by Hyatt, Destination by Hyatt, Hyatt Regency, Hyatt, Hyatt Ziva, Hyatt Zilara, Thompson Hotels, Hyatt Centric, Caption by Hyatt, JdV by Hyatt, Hyatt House, Hyatt Place, UrCove, and Hyatt Residence Club brands, as well as resort and hotel brands under the AMR Collection, including Secrets Resorts & Spas, Dreams Resorts & Spas, Breathless Resorts & Spas, Zotry Wellness & Spa Resorts, Vivid Hotels & Resorts, Alua Hotels & Resorts, and Sunscape Resorts & Spas.